Investment
Features
FeesSafety
Academy
More
Pluang+

Compare J M Smucker Co (SJM) vs 10X Genomics Inc (TXG) Price & Performance

J M Smucker CoTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

J M Smucker Co vs 10X Genomics Inc — how do they compare? J M Smucker Co trades at $117.88 (market cap $12.54B), while 10X Genomics Inc trades at $58.29 (market cap $7.61B). The key difference: J M Smucker Co is the larger of the two by market cap, and J M Smucker Co pays a 3.82% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

SJMTXG
Market Cap
$12.54B$7.61B
Sector
Consumer StaplesHealth
52-Week High
$126.35$58.57
52-Week Low
$89.53$11.34
Enterprise Value
$19.57B$7.14B
Dividend Yield
3.82%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

J M Smucker Co

SJM trades at $118.07, down 1.74% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported mixed fundamentals with strong revenue growth to $8.73B in 2025 but negative net income of -$1.23B. Recent dividend increases and positive earnings beats in Q4 2025 and Q1 2026 highlight management's confidence amid profitability challenges.

Wall Street maintains a cautiously optimistic outlook with 52% analyst buy ratings and a $125.11 consensus target, representing 6% upside. Key risks include persistent negative margins and high debt levels, while opportunities lie in cost controls and Uncrustables growth. The stock offers value at reasonable P/S and P/B multiples with dividend stability.

10X Genomics Inc

TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.

Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.

Returns comparison

Trailing returns across standard periods

About J M Smucker Co

J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.

Read more on SJM

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG